SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
  • 2
    Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst. 1995; 87: 104-109.
  • 3
    Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008; 100: 1184-1187.
  • 4
    Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97: 142-146.
  • 5
    Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007; 25: 3719-3725.
  • 6
    Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337: 161-167.
  • 7
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335: 462-467.
  • 8
    Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007; 25: 4110-4117.
  • 9
    Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26: 1086-1092.
  • 10
    Gaast A, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study [abstract 4004]. J Clin Oncol. 2010; 28( suppl): 15s.
  • 11
    Forastiere AA. Treatment of locoregional esophageal cancer. Semin Oncol. 1992; 19( 4 suppl 11): 57-63.
  • 12
    Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, Mitchell JB. Principles of chemoradiation: theoretical and practical considerations. Oncology (Williston Park). 1999; 13( 10 suppl 5): 11-22.
  • 13
    Jaffer Ajani M, Tanios Berkaii-Saab M, Daivd Bentrem M, et al. National Comprehensive Cancer Network Clinical Pratice Guidelines in Oncology. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed August 2011.
  • 14
    Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20: 1167-1174.
  • 15
    Marks LB, Ma J. Challenges in the clinical application of advanced technologies to reduce radiation-associated normal tissue injury. Int J Radiat Oncol Biol Phys. 2007; 69: 4-12.
  • 16
    Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: a review. Critical reviews in oncology/hematology 2010; 73: 111-125.
  • 17
    Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105.
  • 18
    Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 1999; 24: 31-37.
  • 19
    Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005; 63: 324-333.
  • 20
    Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20: 1167-1174.
  • 21
    Zhu XR, Sahoo N, Zhang X, et al. Intensity modulated proton therapy treatment planning using single-field optimization: the impact of monitor unit constraints on plan quality. Med Phys. 2010; 37: 1210-1219.
  • 22
    Welsh J, Palmer MB, Ajani JA, et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique [published online ahead of print November 29, 2010]. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2010.10.023.
  • 23
    Welsh J, Riley B, Palmera M, et al. Intensity modulated proton therapy allows dose escalation and normal-tissue sparing in locally advanced distal esophageal tumors [published online ahead of print April 4, 2011]. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2010.07.2001.
  • 24
    Shukovsky LJ, Fletcher GH. Time-dose and tumor volume relationships in the irradiation of squamous cell carcinoma of the tonsillar fossa. Radiology. 1973; 107: 621-626.
  • 25
    Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer [published online ahead of print March 22, 2011]. Cancer. doi: 10.1002/cncr.26080.
  • 26
    Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 80: 1350-1357.
  • 27
    Liu SW, Li JM, Chang JY, et al. A treatment planning comparison between proton beam therapy and intensity-modulated x-ray therapy for recurrent nasopharyngeal carcinoma. J Xray Sci Technol. 2010; 18: 443-450.
  • 28
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
  • 29
    Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009; 101: 1261-1268.
  • 30
    Wei L, Xu Z. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer. 2011; 129: 275-284.
  • 31
    Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs. 2009; 18: 1351-1364.
  • 32
    Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radation dose response: results of the M.D Anderson phase II randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105.
  • 33
    Marks LB, Zeng J, Light K, Kahn D, Zhou S. 116: Radiation-Induced Esophageal Stricture Following Therapy for Lung Cancer: Its Clinical Course and Analysis Comparing Stricture Length With Isodose Levels. Int J Radiat Oncol Biol Phys. 2006; 66( 3 suppl 1): S66-S67.
  • 34
    van der Geld YG, Senan S, van Sornsen de Koste JR, Verbakel WFAR, Slotman BJ, Lagerwaard FJ. A four-dimensional CT-based evaluation of techniques for gastric irradiation. Int J Radiat Oncol Biol Phys. 2007; 69: 903-909.
  • 35
    Caudry M, Escarmant P, Maire JP, Demeaux H, Guichard F, Azaloux H. Radiotherapy of gastric cancer with a three field combination: feasibility, tolerance, and survival. Int J Radiat Oncol Biol Phys. 1987; 13: 1821-1827.
  • 36
    Watanabe M, Nagai Y, Kinoshita K, et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion. 2011; 83: 146-152.
  • 37
    McCurdy M, McAleer MF, Wei W, et al. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys. 2010; 76: 816-823.